ACR/ARHP Annual Meeting 2015

Clinician's Role

Adding TNF Inhibitors to MTX Superior to Triple Therapy in RA after Inadequate MTX Response

Among patients diagnosed with rheumatoid arthritis (RA) that does not adequately respond to methotrexate (MTX), adding tumor necrosis factor inhibitors (TNFi) therapy yields better symptom control than triple therapy (MTX + hydroxychloroquine + sulfasalazine), according to a meta-analysis of randomized controlled trials reported at the 2015 ACR/ARHP Annual Meeting.

Investigational Selective IL-23p19 Inhibitor Superior to Ustekinumab in PASI Response in Plaque Psoriasis

Treatment with BI 655066, a selective IL-23p19 inhibitor, resulted in PASI responses superior to ustekinumab in patients with moderate-to-severe plaque psoriasis with or without concurrent diagnosed or suspected psoriatic arthritis, Howard Sofen, MD, from the UCLA School of Medicine, reported at the 2015 ACR/ARHP Annual Meeting.